Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line (Q40636449)

22 September 2017

title

Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line (English)

1 reference

22 September 2017

1 reference

Mitsuko Kotaki

1

1 reference

22 September 2017

Toshiko Motoji

2

1 reference

22 September 2017

Minoko Takanashi

3

1 reference

22 September 2017

Yan-Hua Wang

4

1 reference

22 September 2017

Hideaki Mizoguchi

5

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

22 September 2017

1 reference

22 September 2017

volume

199

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

61-68

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen.

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Growth stimulatory effect of thrombopoietin on the blast cells of acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL( ) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibi

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

STAT signaling in the pathogenesis and treatment of leukemias

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1016/S0304-3835(03)00338-0

7 January 2021

10.1016/S0304-3835(03)00338-0

Identifiers

DOI

1 reference

22 September 2017

1 reference